Treatment of Asthma: The long-acting beta-2-agonists

The long-acting beta-2-agonists have become indispensible in modern asthma therapy. But do they have a fixed position in international guidelines? Here are the proceedings of the 6th Vienna Asthma Forum, when molecular biologists, drug designers, and clinicians discussed the role of three compounds (bambuterol, formoterol, and salmeterol) on a high scientific level. The authors give a fascinating new insight into the physiology of the Beta2- and glucocorticoid receptor, into the considerations before and during drug development, stimulating a vivid discussion among clinical researchers who share a special interest in the most efficacious use of a new therapeutic principle. The original papers and the individual discussions are highly informative and delightful to read.

Collins, S., Wang, S.: Molecular regulation of the Beta2-adrenergic receptor by long- and short-acting Beta-agonists.- Adcock, I.M., Stevens, D.A.: Molecular interactions between glucocorticoids and Beta2-agonists.- Anderson, G.: Formoterol, a new long-acting Beta2-agonist.- Johnson, M.: Development of the long-acting Beta2-agonist, salmeterol.- Svensson, L.-A.: Development of bambuterol; a long-acting, orally active beta-agonist prodrug.- Götz, M.: Development of beta-2 receptors in infancy and childhood.- Villiger, B.: Long-acting beta-agonists in exercise induced asthma.- Boyd, G.: Salmeterol and oral steroid treatment.- Greening, A.P.: Salmeterol and its relationship to treatment with inhaled corticosteroids.- Rudolf, M.: Long term treatment with Formoterol.- Selroos, O.: Comparison of efficiency of bambuterol and salmeterol.- Fabbri, M.L., Beghè, B., Caramori, G., Ciaccia, A.: The future of relievers and controllers in asthma therapy.